Abstracts can be found on-line HERE.

Abstract Submission Guidelines

Deadline for abstract submission through the Submission Website has been extended to: Thursday March 14, 2019 at 23.59 hours (CET).

You should only submit an abstract if you intend to attend the congress. If your abstract is accepted for oral or poster presentation you must register for the congress. The organizers reserve the right to remove from publication any abstract whose author does not register within two weeks of receipt of the acceptance letter.

Acceptance notification

All abstracts received by the indicated deadline will be evaluated by a panel of experts. The submitting author will receive a confirmation of acceptance for oral presentation, poster presentation, or a notice of rejection, by email by the end of March 2019.  

Abstract structure and content

  • Language: Abstracts should be written in English.
  • Abstract title: The title (including spaces) should not exceed 200 characters and should be written in sentence case. Please do not type a full stop (.) at the end of the title.
  • Topics: When asked to select an abstract topic from the list provided, select at least one topic matching the content of your abstract best.
  • Keywords: You may enter a maximum of 6 keywords, describing the content of your abstract for scheduling and indexing purposes. Avoid general terms.
  • Abstract text: The abstract should not exceed 2.500 characters including spaces and punctuation. The abstract title is included in the overall character count. The abstract must be structured in the following five specified subtitles: Introduction, Objectives, Methods, Results and Conclusion. A table can be inserted for inclusion in the abstract.
  • Registration of authors: Names, titles, institutional affiliations, cities, countries and email addresses of all contributing authors should be provided. The presenting author (not necessarily the first author) should be identified.

Abstract topic

  • Advanced therapies
  • Antimicrobials
  • Cancer treatment
  • Cardiovascular treatment
  • Chronic diseases
  • Computerized decision support
  • Drug regulation
  • Drug utilization
  • Drug-drug interactions
  • Education
  • Geriatric treatment
  • Health economy
  • Intensive care treatment
  • Misuse of medicines/substances
  • Nephropharmacology
  • Patient empowerment
  • Pediatric treatment
  • Pharmacogenetics/omics
  • Pharmacokinetics/pharmacodynamics
  • Pharmacovigilance
  • Professional development
  • Psychopharmacology
  • Rare diseases
  • Therapeutic drug monitoring


Abstract Secretariat:
Phone: +31 (0)20 570 9600
Email: eacpt-abstracts@mci-group.com